MaxCyte, Inc. (MXCT)
NASDAQ: MXCT · Real-Time Price · USD
1.500
+0.020 (1.35%)
At close: Sep 17, 2025, 4:00 PM EDT
1.520
+0.020 (1.33%)
After-hours: Sep 17, 2025, 7:03 PM EDT
MaxCyte Revenue
MaxCyte had revenue of $8.51M in the quarter ending June 30, 2025, a decrease of -18.43%. This brings the company's revenue in the last twelve months to $35.75M, down -21.31% year-over-year. In the year 2024, MaxCyte had annual revenue of $38.63M, down -6.44%.
Revenue (ttm)
$35.75M
Revenue Growth
-21.31%
P/S Ratio
4.38
Revenue / Employee
$313,632
Employees
114
Market Cap
159.91M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 38.63M | -2.66M | -6.44% |
Dec 31, 2023 | 41.29M | -2.97M | -6.72% |
Dec 31, 2022 | 44.26M | 10.37M | 30.59% |
Dec 31, 2021 | 33.89M | 7.73M | 29.52% |
Dec 31, 2020 | 26.17M | 4.55M | 21.04% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
MXCT News
- 5 weeks ago - MaxCyte, Inc. (MXCT) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 6 weeks ago - MaxCyte Signs Platform License Agreement with Adicet Bio - GlobeNewsWire
- 6 weeks ago - MaxCyte Announces Strategic Platform Licensing Agreement with Anocca AB to Advance TCR-T Cell Therapy Pipeline - GlobeNewsWire
- 2 months ago - MaxCyte to Report Second Quarter 2025 Financial Results on August 6, 2025 - GlobeNewsWire
- 2 months ago - PHC Announces Exclusive Distribution of MaxCyte® ExPERT™ Platform in Japan - Business Wire
- 3 months ago - MaxCyte and Ori Biotech Collaborate to Improve Manufacturing Efficiencies and Broaden Adoption of Autologous Cellular Therapies - GlobeNewsWire
- 4 months ago - MaxCyte, Inc. (MXCT) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 4 months ago - MaxCyte Reports First Quarter 2025 Financial Results and Reiterates Full Year 2025 Guidance - GlobeNewsWire